Lynnette Henshaw, PharmD, BCOP

Clinical Pharmacy Specialist-Lymphoma @MSKCancerCenter 🧬🩸💊| BCOP | Cancer survivor🎗

[James Davis, PharmD, BCOP @thisisJamesD]

🔥🔥🔥🔥🔥 Nivo-AVD is here to stay
https://t.co/6w5fRxqcSq

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

@JillLykon @Benyam_Muluneh @HemeOncPharm @HOPArx @RBeechPharmD @thisisJamesD @JBergRx @JeffBaronPharmD @KelleyCPharmD @kczmj @KoontzOncology @olivia__white1 @TexBuckeyeBCOP We don’t have EPIC yet (go live in Feb. ‘25), but most of our multi day regimens get ordered/verified once for multiple doses. We only use separate specific day orders for certain regimens (e.g. pegaspargase for SMILE). Not sure how our Epic will look 😬

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

My Cycle for survival ride is almost here, please consider donating if you haven’t already! 🚴🏼‍♀️🎗️
https://t.co/FiNepwphlM

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

Please donate to my team! @Cycle4Survival and raise money for rare cancer research at @MSKCancerCenter. You can help build a better future for people worldwide. https://t.co/FiNepwphlM

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

🥹🥹So glad to have these girls by my side in Boston for the last 3 years 🩷🩷

[東京マーケット眼（め） @AvaCPharmD]

Just like that I’m (almost) the last 2021 BMCPharmRes standing!!! We will miss you @lynnalidomide 🥹💕

[Amyloidosis Research Consortium @Amyloidosis_ARC]

🔬💊 Happening Now: The #AmyloidosisForum will consider how to effectively design #ATTR #amyloidosis trials as the first generation of drug approvals have reshaped the research landscape.

Join us and 60+ speakers all day today: https://t.co/mzUX1G1TCN

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

If you are wondering how Belantamab Mafodotin did in real world, check out our systematic review article @japacademy @UAMSMyeloma
#mmsm

➡️https://t.co/UiW2AskiEp

[Amyloidosis Research Consortium @Amyloidosis_ARC]

Ongoing & future trials for #ATTR #amyloidosis drugs face challenges their predecessors didn't. Access to new treatments is getting more complex.

Next week's #AmyloidosisForum will discuss these and other problems & solutions in ATTR drug development: https://t.co/R7suiCWCGW

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

So proud of our residents for all their hard work on this QI initiative ! Expanding access to care 🏥💊and decreasing time off cancer therapy due to HTN 📉#oncopharm #twitteRx #proudmentor

[BMC Pharmacy Residency @BMCPharmRes]

Congratulations to @sitarabine and @jessica_hodgen for the first place poster @MAPharmacists #MASHP23 annual meeting! Excellent project expanding the pharmacists scope, enhancing patient safety and access to oncologic therapies! #PharmRes #TwitteRx

[BMC Pharmacy Residency @BMCPharmRes]

Congratulations to @sitarabine and @jessica_hodgen for the first place poster @MAPharmacists #MASHP23 annual meeting! Excellent project expanding the pharmacists scope, enhancing patient safety and access to oncologic therapies! #PharmRes #TwitteRx

[Bernie Marini @Berninini]

Pola+R-CHP approved for upfront DLBCL. However, no improvement in OS or QOL compared to standard R-CHOP. We’re talking about a 6.5% absolute difference in 2-year PFS here with a major increase in cost. This is a marginal gain, not a game changer 🤷🏻‍♂️ #lymsm https://t.co/1vDKr99UUR

[Laura Vater, MD, MPH @doclauravater]

Just a reminder that you can do everything “right” and unfortunately still get cancer. Never blame or shame someone dealing with a cancer diagnosis.

[Tori Arsenault, PharmD ✨🚑🫀❣️ @rxtoriarsenault]

⚠️ so many reasons not to do this
anticholinergic toxicity is NO joke!
….anyone have physo?! I’ve never seen it used!

any pearls from #toxtwitter #MedTwitter #TwitteRx ?

[Jasmine Patel @JPatel_PharmD]

I really was this happy to be here 🤪#HOPAAC23 #oncopharm #TwitteRx

[Sita Bhatt @sitarabine]

Had a great time at #HOPAAC23 with some of my favorite people!

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

Had a great time presenting my research at the poster session last night @HOPArx #HOPAAC23 #oncopharm #twitterx

[Jasmine Patel @JPatel_PharmD]

Very proud of @sitarabine for presenting our QIP at #HOPAAC23 on Optimizing the Management of Prostate Cancer Treatment-Related HTN 🫀in a highly underserved patient population! Also awarded 1 of 5 Quality in Oncology Care certificates 🏅#HOPA2023 @BMCPharmRes @The_BMC

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

Very honored to speak at #hopa2023 today 👩🏼‍⚕️💊 shout out to @CamilleVEdwards for her help in putting together this project! 🩸Excited to see what the rest of the conference holds @HOPArx #twitterx #oncopharm

[Dave Hughes @dhughesPharmD]

Another first timer presentation at #HOPAAC23 ! Proud mentor moment for a past resident and now friend 🥲#TwitteRx #oncopharm @lynnettehenshaw

[Lynnette Henshaw, PharmD, BCOP @lynnalidomide]

Our PGY-2 oncology pharmacy residency is entering phase 2 of the match, we have 1 open spot 💊🩸
If you or anyone you know is interested you can reach out directly to myself or @JPatel_PharmD via direct message or email
More info on our website
https://t.co/FLeOXYM2yU #twitteRx

[BMC Pharmacy Residency @BMCPharmRes]

Boston Medical Center has a few programs entering Phase II

Be sure to check us out if your interested in:
- Oncology (carT, gene therapy, Outpatient mng)
-IM (TOC, unique pop, SUD)
-1/2 HSPAL +MS (system opportunity in compact & adaptable sys)

https://t.co/620OC4Sklq